Harwich Port, Massachusetts, United States Related Funds
| Fund Name | Location |
| Acorn Bioventures | New York, New York, United States |
| Ascend Capital Partners | - |
| At One Ventures | - |
| Barco Healthcare | - |
| Emurgo | Japan, Tokyo |
| Flybridge Capital Partners | Boston, Massachusetts, United States |
| Garden State Life Sciences Venture | Pennsylvania, Philadelphia, United States |
| Impact Ventures Hungary | Budapest, Hungary |
| JOLT | Canada, Ontario, Toronto |
| Koch Equity Development | Kansas, United States, Wichita |
| Naseel | - |
| National Building and Marketing | Ar Riyad, Riyadh, Saudi Arabia |
| Radianx Capital | - |
| Sustainable Ventures | England, London, United Kingdom |
| TechSquare Labs | Atlanta, Georgia, United States |
| The Refiners | California, San Francisco, United States |
| Vetrargil | Gullbringusysla, Iceland, Reykjavík |
| Zhuhai Gaoxin Chuangye Touzi Co., Ltd. | - |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
AnHeart Therapeutics | $61M | 14 Dec 2021 | Shangcheng District, Zhejiang, China | ||
ShouTi | $100M | 20 Oct 2021 | Shanghai, China | ||
Insilico Medicine | $255M | 22 Jun 2021 | Hong Kong Island, Hong Kong, China | ||
Harbour Biomed | $102M | 09 Jul 2020 | Shanghai, China |
– ShouTi Inc. announced the close of a $100m Series B financing round.
– The round was led by BVF Partners. Additional new investors include Casdin Capital, Cormorant Asset Management, Janus Henderson Investors, Lilly Asia Ventures, Monashee Capital, Sage Partners, Stork Capital, Surveyor Capital (a Citadel company), TCG X, Terra Magnum Capital Partners, Woodline Partners, and co-founder and strategic partner Schrödinger.
– Existing investors also participated in the financing, including Eight Roads, F-Prime Capital Partners, Qiming Venture Partners, Sequoia Capital China, TF Capital and Wuxi AppTec.
– Visus Therapeutics from Seattle develops innovative ophthalmic therapies to improve vision for people around the world.
– The company raised $20m in funding.
– The round was led by LSP in Amsterdam with participation from Sage Partners of Hong Kong, Johnson & Johnson Innovation -JJDC, Inc. and other inside investors.
– The new investment will be used to advance its clinical and commercial efforts for lead asset BRIMOCHOL under investigation for presbyopia as well as new research and development activities in its drug development pipeline.
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
AnHeart Therapeutics | $61M | 14 Dec 2021 | Shangcheng District, Zhejiang, China | ||
ShouTi | $100M | 20 Oct 2021 | Shanghai, China | ||
Insilico Medicine | $255M | 22 Jun 2021 | Hong Kong Island, Hong Kong, China | ||
Harbour Biomed | $102M | 09 Jul 2020 | Shanghai, China |
